Blue Jet Health

Blue Jet Healthcare reported Q2 FY26 revenue from operations of ₹165 crores, marking a significant 54% sequential decline and a 21% year-on-year decrease. This was primarily attributed to increased transit times affecting revenue recognition in the Contrast Media segment and phasing of orders in PI-API. Despite the Q2 dip, H1 FY26 revenue stood at a robust ₹518 crores, demonstrating a 40% year-on-year growth. EBITDA for Q2 was ₹60.1 crores with a 36% margin, up 14% YoY, while H1 EBITDA reached ₹182 crores (35% margin), growing 41% YoY, indicating sustained profitability despite revenue fluctuations.

The Contrast Media segment recorded Q2 revenue of ₹81 crores, down 17% QoQ. Management clarified that only 55% of Q2 production was recognized as sales due to extended transit times (60 days vs. 35-40 days previously), with the remainder in transit for Q3 recognition. H1 Contrast Media revenue was ₹178 crores, consistent with the prior year. The Pharma Intermediates & API (PI-API) segment saw Q2 revenue of ₹42 crores, an 80% QoQ decline due to phasing, but H1 revenue surged 113% YoY to ₹255 crores, driven by cardiovascular drug intermediates. High-intensity Sweeteners grew 7% sequentially in Q2 and 3% YoY in H1.

The company is executing significant capacity expansion plans. The Mahad backward integration facility, a highly engineered plant for continuous flow synthesis of KSMs for Contrast Media, is on track for commissioning by H2 FY26. The CAPEX for this facility has been revised upwards to ₹300 crores (from ₹250 crores) due to automation, with ₹135 crores already incurred in H1. Additionally, a state-of-the-art R&D center is planned in Hyderabad with a CAPEX of ₹40 crores to support new chemistry platforms like peptides and biocatalysts.

Blue Jet Healthcare has acquired a 103-acre land in Vizag for a globally competitive CDMO facility. Phase-I, with an approximate CAPEX of ₹1,000 crores, is planned to be completed by FY28. This phase will include four blocks: two for Contrast Media, one for a new high-intensity Sweetener, and a multipurpose block for new chemistries, including peptide fragments for GLPs. The groundbreaking is expected in the coming quarter, with capacities coming on stream in phases from FY28 onwards, aiming to add 1,000 KL capacity over the next 2-3 years.

Management highlighted promising new product developments. A new high-intensity Sweetener, with a global market size of approximately $1 billion, is being developed, with Blue Jet aiming for a 10% market share. This product will primarily be manufactured at the Vizag facility. The company is also tracking 20 RFPs, including 6 high-conviction Phase-III leads in the chronic space and an NCE for MRI, with commercialization for three late-stage Onco and CNS candidates expected by FY27, each representing a market opportunity of over $1 billion individually.

Blue Jet Healthcare maintains a strong financial position, being debt-free with ₹341 crores in liquidity, primarily funding its expansion through internal accruals. Despite quarterly volatility, the company aims to maintain an EBITDA margin of around 35% for the full year. Gross margins for Q2 were 65% (vs. 48% in Q1), and H1 gross margins were 54%. Management emphasized that while quarterly variations are natural, the medium to long-term visibility remains strong, supported by order book momentum, customer lock-ins, and new validations.